As shown in Fig 7, the majority of the tumours from the TP53INP1, LATS2 and CD44 silencing group were poorly differentiated, and the tumour area percentage were more than 80%, while most of the tumours from the MIA-V control group were well differentiated, and the tumour area percentage were less than 20%. This evidence concerns the gene CD44 and neoplasm.